The Failure and Potential of Home Diagnostics
Executive Summary
Even for experienced companies, home testing has been a tough business, and expectations set by the success of blood glucose monitoring and pregnancy have been impossible for other tests to meet.
You may also be interested in...
What’s Next? Five Things To Look Out For In October
Generics Bulletin previews the most notable and anticipated events for October 2023.
Pink Sheet Podcast: Adcomm Rejects NurOwn For ALS, FDA In Shutdown Mode, Limited Price Negotiation Savings
Pink Sheet reporters and editors consider the fallout from Brainstorm Cell Therapeutics Inc.’s negative US FDA advisory committee decision on its ALS drug, the impact of a government shutdown on the agency, and a study showing only a limited possibility for significant savings in the first round of Medicare price negotiations.
Increase In Subpar Pharmaceutical Repacking Draws US FDA Attention
Foreign tablets, active pharmaceutical ingredient residues and failed line clearance plagued operations at repackers that received FDA warning letters in FY 2023.